research COVID-19-associated Telogen Effluvium After Hospital Discharge: A Prospective Cohort Study.
Many severe COVID-19 patients experienced temporary hair loss, but most regrew hair within six months.
Search
for
Sort by
Research
300-330 / 1000+ results 
research Assessment of semen quality in patients with androgenetic alopecia in an infertility clinic
Men with severe hair loss may have poorer sperm quality.
research The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity
Alopecia areata greatly affects people's life quality, mental health, and work life.
research Subclinical Atherosclerosis in Alopecia Areata: Usefulness of Arterial Ultrasound for Disease Diagnosis and Analysis of Its Relationship with Cardiometabolic Parameters
Alopecia areata patients have a higher risk of subclinical atherosclerosis, and carotid ultrasound can help assess their cardiovascular risk.
research Perceived Stigma Among Adults With Alopecia Areata in the United States
Alopecia areata causes significant stigma and emotional distress, with many affected individuals not receiving adequate support or treatment.
research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research British Association of Dermatologists living guideline for managing people with alopecia areata 2025
The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Photochemotherapy and Alopecia Areata
Some people with severe hair loss saw hair regrowth after a specific light and drug treatment.
research Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.
research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Synthetic hair reactions and treatment of complications: Case reports
Synthetic hair implants can cause severe scalp problems and removing them improves conditions; natural hair transplants are safer and more effective.
research A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research More is not always better in hair growth factors. epidermal growth factor: hair growth factor involved in alopecia areata pathogenesis
Too much epidermal growth factor can cause hair loss.
research Perceived Stigma and Mental Health Disorders Among Adults With Alopecia Areata Living in Japan
Alopecia areata significantly affects mental health and quality of life, with many feeling stigma and few receiving adequate treatment.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness
A gene called HDAC9 might be a new factor in male-pattern baldness.
research Impact of hair loss on quality of life and mental health: a comparative study of androgenetic alopecia and alopecia areata
Hair loss significantly affects quality of life and mental health, causing anxiety and depression.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Alopecia Areata: Pathogenesis, current treatments, and future perspectives
Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
research Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
Higher MPV and CRP levels may indicate more severe alopecia areata.
research Evaluation of serum zinc level in patients with Alopecia Areata
Lower zinc levels are linked to more severe hair loss in alopecia areata.
research SYSTEMATIC REVIEW OF PHARMACOTHERAPY STRATEGIES IN THE MANAGEMENT OF HIDRADENITIS SUPPURATIVA
Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
research Alopecia Areata: An Updated Review for 2023
Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease
Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.